Background: Public health interventions are increasingly being evaluated for their cost-effectiveness. Such interventions act 'upstream' on the determinants of ill health and commonly reduce the incidence of several diseases. Diseases that share determinants are usually correlated at an individual level, which we observe as comorbidity. This paper is motivated by the problem of estimating comorbid disease state risks when only single disease risk estimates are available. Methods: A case study is presented based on a physical activity cost-effectiveness model. The correlation between the risk of coronary heart disease, stroke and diabetes is estimated from cross sectional data using a Bayesian multivariate probit model. This is then combined with disease specific marginal baseline risks and intervention effects to give comorbid disease state risks. The expected numbers of QALYs gained through avoiding the comorbid states is estimated from disease specific utility data under a range of assumptions. Finally, the incremental benefit of physical activity is calculated under these utility assumptions. The difference in incremental benefit due to the intervention's impact on reducing or increasing the disease risk correlations is explored in a sensitivity analysis. Results: If comorbidity is not taken into account, incremental benefit is overestimated compared with all scenarios in which the comorbidity is included in the model. Overestimation is greatest when physical activity is assumed to reduce disease state co-occurrence as well as disease risk. Conclusions: The proposed method reduces overestimation of benefit and allows the sensitivity to different assumptions about the correlation between disease risks to be determined. T he motivation for this article is the problem of estimating the risks of comorbid disease states when only single disease risk estimates are available from empirical studies. We initially recognized this difficulty in the context of parametrizing a costeffectiveness model for a public health physical activity-promoting intervention that was expected to have an impact on the risk of several different diseases. We expect, though, that the problem of finding comorbid disease state estimates, and our proposed solution, will be applicable in many different health economic modeling contexts, not just those classified as public health.
Public health interventions are generally directed ''upstream'' at the determinants of ill health and as such are commonly expected to have an impact on more than 1 disease. 1 An example of an upstream determinant of ill health is an individual's level of physical activity, with a sedentary lifestyle being associated with a range of diseases, including stroke, diabetes, and coronary heart disease (CHD). If we wish to evaluate the cost-effectiveness of a physical activity-promoting intervention, we therefore need to take account of the impact of the intervention on the costs and benefits associated with more than 1 disease.
The UK National Institute of Health and Clinical Excellence (NICE) has evaluated the cost-effectiveness of physical activity-promoting interventions as part of its Public Health Guidance program. 2 In the economic model published in support of the physical activity guidance, 3 4 diseases were considered-CHD, stroke, diabetes, and colon cancer-and a choice was made to evaluate the incremental costs and benefits of physical activity-promoting interventions separately for each disease. The total incremental cost and total incremental benefit of the intervention were then assumed to be the sums, respectively, of the 4 disease-specific incremental costs and benefits. This approach of summing incremental costs and consequences calculated separately for a number of diseases is common to a number of other NICE Public Health guidance economic evaluations [4] [5] [6] and is attractive because evidence required to inform parameter values in the model is often disease specific. There may be very few data available that relate to the effectiveness of the intervention in reducing the risk of the comorbid disease states (e.g., CHD and diabetes) or the costs and consequences of those states.
If we assume that the risks and treatment effects for the single disease states in the above models are marginal risks and treatment effects, then summing the expected population costs and consequences that relate to the impact of the intervention on these marginal risks is equivalent to assuming that where comorbidity exists, the costs and consequences associated with the separate diseases are additive at the individual level. To give an example, this means that the cost saved when an individual person avoids both CHD and a stroke is assumed to be the same as the sum of the costs saved when one person avoids CHD and another avoids a stroke. Likewise, the benefit gained by that individual is assumed to be equal to the sum of the benefits gained when one person avoids CHD and another avoids a stroke.
To see why this additive assumption is unlikely to hold for benefits, first consider a simple example in which benefits are measured in life-years gained. Assume that an intervention has the effect of preventing 2 diseases, A and B. The average age of death is 60 years for a person with disease A and 65 years for a person with disease B. Without disease, the average age of death is 75 years. The number of life-years gained is 15 for a person avoiding A and 10 for a person avoiding B. It is difficult to justify why a person avoiding both A and B would gain 25 years of life.
Second, consider an example in which an intervention has an effect on quality of life, but not its length, through its effect on 2 diseases: A and B. Health state utility valuations are used as the measure of quality of life. Let's imagine that disease A is associated with a utility weight of 0.7 and disease B with a utility weight of 0.6, whereas the state of absence of A and B is associated with a utility weight of 0.9. Calculating the population expected benefit under the additive assumption would be equivalent to assuming that a person who avoids both A and B for 1 year gains (0:9 À 0:7Þ + ð0:9 À 0:6Þ = 0:5 qualityadjusted life years (QALYs).
There is no inherent justification for these additive assumptions for length and quality of life. In the first case a better assumption may be that the number of life-years gained when a comorbid state is avoided is the same as the number of life-years gained when the component disease that has the earliest age of death is avoided. In the second case there are again more compelling models for comorbid health state utility weights, both for theoretical reasons 7 and based on empirical data. 8 A common assumption is that the utility weight for a joint health state is the product of the utility weights for the individual component states. In the same way, costs accruing because of the prevention of multiple diseases are unlikely to be simply additive, and we may envisage a range of more plausible models.
If we do decide to base our analysis on a nonadditive assumption regarding the comorbid costs and consequences, we will need to quantify the risks of these comorbid disease states under both the intervention and the baseline comparator, and as stated above this requirement provides the motivation for our article. To estimate comorbid disease state risks, we need to know something about the degree of cooccurrence (correlation) between the diseases at an individual level, something that is not obtainable from the disease-specific studies that are usually used to inform baseline disease risks and treatment effects.
Given that we may not be able to find direct estimates for the comorbid disease state risks in the intervention and comparator groups, we propose a method for combining estimates of the marginal disease-specific baseline risk and treatment effects with information relating to the correlation between disease risks derived from an external source. To illustrate our method, we have created a simplified version of the NICE physical activity model as a case study that runs throughout the article.
CASE STUDY
Our case study is loosely based on the economic model published as part of the NICE physical activity guidance. 3 For simplicity of illustration we consider only the incremental benefits (in QALYs) of physical activity (refered to as the ''intervention'') over a sedentary lifestyle (''baseline''). We also restrict ourselves to considering the effect of physical activity on 3 diseases: CHD, stroke, and diabetes.
The Marginal Economic Model
In this section we describe our simplified version of the NICE guidance economic model and the evidence used to inform the parameter values. We call this the ''marginal'' model since it is parametrized in terms of the marginal disease risks and incremental benefits for the 3 diseases.
We are interested in the incremental health consequences (in QALYs) of the intervention compared with baseline. The model assumes 4 disease states: well, CHD, stroke, and diabetes. Each state is associated with a population mean utility in QALYs, shown in Table 1 . Utilities were derived from data reported in the NICE modeling document. 3 The (baseline) incident risks of CHD, stroke, and diabetes in a sedentary population, indexed j = 1; . . . ; 3, are denoted b j , and the treatment effects (as relative risks) are denoted RR j (see Table 2 ). Ideally these estimates would be derived from studies conducted in populations that are similar to the population of interest. Given b j and RR j , it is then possible to derive estimates for the risks after the intervention, t j = b j × RR j , and the absolute risk differences, t j À b j (see Table 3 ).
The marginal model assumes the overall incremental benefit in QALYs, denoted DE, is
where u j is the population mean expected number of QALYs experienced by someone with disease j. Those who are well have an expected number of QALYs of u 0 , and u j À u 0 is therefore the expected number of QALYs lost by an individual who has disease j. Evaluating this model with the parameter values in Tables 1 to 3 leads to an estimated incremental benefit of 0.602 QALYs. This can be interpreted as an additional 0.602 years of perfect health, or an additional n × 0:602 years of health with a utility weight of 1 n . Propagating parameter uncertainty through the model using standard Monte Carlo-based probabilistic sensitivity analysis with 10,000 samples leads to a 95% credible interval (CrI) of 0.114 to 1.005 QALYs. For the purposes of the uncertainty analysis, we assumed normal distributions for the baseline risks, b j , and benefits in QALYs, u j . For relative risks, RR j , we assumed log-normal distributions since these are ratio measures bounded at zero.
Problems With the Marginal Model
The 3 disease states-CHD, stroke, and diabetesclearly are not mutually exclusive since it is possible for an individual to have more than 1 of these diseases; however, there are no parameters in the model that relate to the risks or utilities of the comorbid states. By evaluating overall incremental benefit via Equation 1, we are implicitly making the assumption that the benefit of avoiding a comorbid state (e.g., the state of CHD and diabetes) is the sum of the benefits of avoiding each of the component disease states. If we wish to avoid making this additive assumption, we need to estimate the risks and utilities for the complete set of mutually exclusive joint disease states rather than just the marginal risks and single disease-specific utilities. Given 3 diseases, there are 2 3 = 8 mutually exclusive joint disease states, including the state of good health. In our example these states are well, CHD alone, stroke alone, diabetes alone, CHD and stroke, CHD and diabetes, stroke and diabetes, and all 3 diseases. We refer to this set of 8 mutually exclusive disease states as the joint disease states, and the parameters that relate to these states are denoted by a superscript asterisk. We refer to the 4 disease states within this set that consist of more than 1 disease as the comorbid states.
If we are able to estimate parameters for the joint states, our new model for incremental benefit will be
where k indexes the 8 mutually exclusive joint disease states (well, CHD alone, stroke alone, diabetes alone, CHD and stroke, CHD and diabetes, stroke and diabetes, all 3 diseases), b Ã k is the baseline risk of disease state k, t Ã k is the intervention risk of disease k, and u Ã k is the expected number of QALYs for an individual in disease state k. The disease-free state is indexed k = 0. Equation 2 can be written in the same form as Equation 1 by recognizing the following. Because
As a result we can write
Estimating the Utilities for the Joint
The utility, in QALYs, for a disease state is determined by both length and quality of life. We assume that we do not have empirical evidence that relates to the mean length of life for the comorbid states, and nor do we have quality of life data for the comorbid states. We therefore must model these parameters based on the length and quality of life data for the single diseases.
As regards length of life, we assume that the age of death for an individual who has more than 1 disease is the earliest of the ages of death for the single diseases that make up the individual's comorbid disease state. As regards quality of life, we explore 3 models based on theoretical and empirical arguments in the literature. 7, 8 Joint state QALY model 1-multiplicative. The quality of life (as measured by an EQ5D utility weight) for each comorbid state is the product of the utility weights for the single diseases that make up the comorbid state. Joint state QALY model 2-minimum. The quality of life weight for each comorbid state is the minimum of the utility weights for the single diseases that make up the comorbid state. Joint state QALY model 3-additive decrement.
The reduction in quality of life weight between the well state and each comorbid state is the sum of the utility decrements (i.e., the difference in utility weight between well and disease) for the individual diseases that make up the comorbid state.
Note that Model 3 differs from the marginal model in that total benefits in QALYs are assumed to be additive under the marginal model, whereas in Model 3 the additive decrement assumption applies 
Note: CHD, coronary heart disease; CrI, credible interval.
only to quality of life weights. Length of life decrements are not additive under any of the joint state QALY models. Table 4 shows the estimated utility in QALYs for the 8 joint states calculated under these 3 models.
Estimating the Joint Disease Risks, b Ã k and t Ã k
We assume that we have estimates of the baseline risks and treatment effects for the 3 single (marginal) disease states-CHD, stroke, and diabetes-that are relevant to our population (we call this Data Set A). We do not have information on the baseline risks and treatment effects for the comorbid disease states since the studies we have found are disease specific. However, we do have information from elsewhere that relates to the correlation between our 3 diseases in the form of individual-level data from a crosssectional study (we call this Data Set B). If the correlation information in Data Set B can be combined with the estimates of the marginal baseline risks and treatment effects in Data Set A, then we can estimate the 8 joint disease risks we require.
The presence or absence of the 3 diseases in Data Set B represents correlated binary data. However, describing correlation between binary variables is not straightforward. The Pearson correlation coefficient will depend on the population proportions of the 3 diseases and instead of varying between À1 and + 1, as it does for continuous data, will lie on a narrowed interval that is not symmetric about 0, potentially making interpretation of the measure difficult. Ideally, we would like a measure of correlation that is independent of the marginal population proportions of the 3 diseases and that lies between À1 and + 1 for ease of interpretation.
One solution to this problem is to link the correlated binary outcomes to a latent variable with a multivariate normal distribution, therefore allowing the correlation structure in the data to be expressed through the covariance matrix of the multivariate normal distribution. If the covariance matrix is expressed in correlation form, then we have a measure that fulfills both our criteria above. Linking a binary outcome to an underlying multivariate normal latent variable is an example of the use of a multivariate probit model, discussed in detail by Chib and Greenberg (1998) 9 and by Albert and Chib (1993) . 10 To illustrate the multivariate probit model we first assume that we have data, y ij , on i = 1; . . . ; n individuals, relating to the presence or absence of j = 1; . . . ; 3 diseases. The binary data y ij are linked to the latent variable, denoted z ij , via y ij = Iðz ij > 0Þ, where Ið · Þ is the indicator function, taking value 1 if z ij > 0 and 0 otherwise. The latent variable vector for each individual i is denoted z i = ðz i1 ; z i2 ; z i3 Þ, and these are assumed to have a trivariate normal distribution; that is, that they are realizations of a random variable, Z i , with Z i ∼ N 3 ðμ;ΣÞ. Here, μ = ðm 1 ; m 2 ; m 3 Þ describes, on the latent continuous scale (i.e., À∞ to + ∞ ), the marginal disease risks in the cross-sectional study population, and the covariance matrix Σ models the dependency between the binary disease states. The latent variable Z i could be envisaged as quantifying an underlying degree of propensity for each disease on a continuous scale. If the propensity for disease j exceeds some threshold, then that disease occurs.
Estimating Σ for Our Case Study
We have cross-sectional data on 18,553 individuals that relate to the presence or absence of CHD, stroke, and diabetes. These data come from the Health Survey for England (HSE) 2003. 11 The HSE is a large, annually conducted survey of a representative sample of the population of England that aims to provide information on the health status of the population.
We took a Bayesian approach and estimated the correlation between the risks of CHD, stroke, and diabetes from the HSE data using Chib and Greenberg's multivariate probit model (see Appendix A) . Appendix B shows the annotated BUGS code that we ran in OpenBUGS 3.0.8. 12 We placed the following weak priors on the mean and correlation parameters: μ ∼ N 3 ð0; 10 6 I 3 Þ and Σ ∼ IWðI 3 ; 3Þ, where I 3 is the 3dimensional identity matrix and IW is the inverse Wishart distribution, parametrized in terms of an inverse scale matrix and a number of degrees of freedom. 13 We ran 3 Markov chains, each with a different set of initial parameter values. The Brooks-Gelman-Rubin diagnostic suggested adequate convergence after a burn-in of 50,000 samples. 14, 15 The samples from the posterior distribution of the parameters of the correlation matrix, Σ, were highly autocorrelated. The presence of positive autocorrelation in a Markov chain Monte Carlo (MCMC) increases the number of samples required to achieve some prespecified level of accuracy in the estimates of the mean and variance of the posterior distribution. 16 This is because each successive iteration in an autocorrelated chain provides a smaller amount of independent information than each iteration in an uncorrelated chain.
The chain is sometimes thinned to reduce autocorrelation, which is appropriate if the size of the sample that can be processed is fixed at some level, usually because of limited computer memory storage. Given a chain of length N and a thinned sample set of length n from that chain (i.e., thinning the chain keeping every k th sample where k = N n ), it is better to base inference on the thinned sample set of size n than on n consecutive samples from the unthinned chain. However, inferences based on a thinned sample set of size n will always be less accurate than inferences based on the full unthinned chain of length N. 17 We generated 250,000 samples from the 3 MCMCs after burn-in and estimated means and variances for the parameters of the correlation matrix, Σ, using the whole sample set. We then selected every 25th sample (i.e., 10,000 samples in total) for use within the economic model, given that propagating all 250,000 samples through the economic model in a probabilistic sensitivity analysis (described below) would have taken a prohibitively long time. Thinning the chain in this way, rather than simply selecting the first 10,000 samples, reduced the autocorrelation in the sample set used within the economic model and therefore increased the accuracy of the probabilistic sensitivity analysis.
The marginal risks calculated from the HSE data set were 46 per 1,000 for CHD, 20 per 1,000 for stroke, and 33 per 1,000 for diabetes, and the correlations between the disease risks on the latent scale were 0.509 (95% CrI, 0.459-0.558) for CHD and stroke, 0.441 (95% CrI, 0.391-0.490) for CHD and diabetes, and 0.400 (95% CrI, 0.338-0.460) for stroke and diabetes.
Combining Σ With Marginal Risks to Calculate Joint Disease State Risks
Once we have estimated Σ, we must then combine this correlation information with the marginal disease risks b j and t j to give the baseline and treated risks b Ã k and t Ã k for the k = 0; . . . ; 7 joint states. There is no closed-form analytical solution to this problem, but the simulation based solution described below is straightforward.
The marginal risks b j and t j are first transformed onto the latent scale via the inverse normal cumulative distribution function, F À1 ð · Þ,
To obtain the joint disease risks for baseline we draw a large number ði = 1; . . . ; mÞ of samples,
These samples are transformed onto the binary scale via the indicator function y ij = Iðz ij > 0Þ, giving a correlated binary data set with marginal disease risks b j and a correlation structure that reflects the individual-level disease dependence that we require. The joint risks b Ã k are obtained from the y ij via the expressions in Table  5 . The 8 joint absolute risks for the intervention group t Ã k are calculated in the same manner. This is done using the same correlation matrix, Σ, as for the baseline risks, or using a different correlation matrix if there is evidence to support a different dependence structure after the intervention. Table 6 shows the estimated absolute risk for each joint disease state at baseline (no physical activity) and with physical activity (expressed as numbers of cases per 1,000 population) under 2 assumptions: first, that disease risks are independent (i.e., that Σ = I 3 ) and, second, that the correlation is the same as that in the HSE population.
The risk of being in either a comorbid state or the no-disease state is greater under the correlated risks assumption than under the independence assumption, reflecting the positive correlations in risks between all 3 marginal disease states.
Calculating Incremental Benefit Under a Range of Scenarios
We explored a range of scenarios in which we combined different assumptions about disease risk correlation structure with different models for the comorbid disease states utilities.
In the first 3 scenarios we considered disease risks to be independent, both at baseline and after the intervention. In the second set of 3 scenarios we considered both baseline and treated risks to be correlated, with the degree of correlation estimated from the HSE data. Because there may be good reasons for assuming different correlation structures in the baseline disease risks and treated risks, we wanted to explore 2 further scenarios. Baseline risks were assumed to have the same correlation structure as that estimated from the HSE data, but treated risks were assumed, first, to have a higher degree of correlation (by a factor of 10%) and, second, to have a lesser degree of correlation (by a factor of 10%).
For each of the 4 sets of scenarios we assumed the 3 models described above for comorbid disease state utilities: multiplicative, minimal, and additive. In each of the resulting 12 scenarios we calculated the incremental benefit via Equation 2.
Probabilistic Sensitivity Analysis
To conduct a probabilistic sensitivity analysis, uncertainty in the estimates for the baseline risk and treatment effect parameters, as well as for the correlation matrix, Σ, must be propagated through the model. Because the joint risk parameters b Ã k and t Ã k are calculated via simulation, 2 levels of simulation are required to determine the uncertainty in the model output. See Halpern and others 18 for a discussion of such nested models. Samples are drawn from the posterior distributions of the parameters u j , b j , RR j and Σ in an outer loop, and for each run of the outer loop, the joint risk parameters b Ã k and t Ã k are estimated through a large number of runs of an inner, nested, loop. For the purposes of our case study we drew 10,000 samples from the outer loop parameters and based each estimate of b Ã k and t Ã k on 2,000 inner loop samples.
RESULTS
If the benefits of the intervention are calculated separately for each disease and then summed (the marginal approach as taken in the NICE models identified in the introduction, 2, [4] [5] [6] ), then the overall incremental benefit calculated via Equation 1 is estimated to be 0.602 (95% CrI, 0.114-1.005). This marginal approach overestimates the benefit of the intervention compared with that predicted in all our 12 scenarios ( Table 7 ). The overestimation is largest when the marginal approach is compared with the scenario in which the minimal model was used to estimate utilities of the comorbid states, the baseline risks were correlated, and the correlation in the risks was reduced after the intervention. The overestimation is least in the case where the additive decrement assumption was used for comorbid state utilities and the disease risks were considered to be independent.
In general, the overestimation of the marginal approach will be worst when there is a high degree of positive correlation between disease risks at baseline that then weakens after the intervention. To see why, consider the following. A large positive correlation between diseases at baseline implies that many individuals who are ill will have more than 1 disease. If the correlation in disease risk is smaller in the intervention group than in the baseline group, this implies that the intervention is protective against the comorbid states and that many instances of a comorbid disease state would be avoided if the intervention were implemented. Under the marginal model, avoiding a comorbid state is overvalued, primarily because of the unrealistic assumption of additivity of life years gained, and this overvaluation leads to the overestimation of incremental benefit. 
Note: CHD, coronary heart disease; DM, diabetes mellitus.
DISCUSSION
Our analysis suggests that the marginal approach to modeling the impact of an intervention on multiple diseases is likely to overestimate the overall benefit, unless benefits really are additive at an individual level. Even if diseases are assumed to be independent, the marginal approach will still lead to overestimation of benefit because the marginal approach assumes an additive decrement of length of life as well as quality of life for comorbid states.
Overestimation by the marginal model will be avoided only if the diseases are mutually exclusive.
The differences between the results of the marginal model and the 12 alternative scenarios we present in our case study are modest. However, even small differences in costs and benefits may be important if the overall cost-effectiveness is close to the decision threshold. This holds even when credible intervals overlap since the mean incremental costs and benefits are of primary importance to the decision maker. 19 The ideal approach to modeling cost-effectiveness in the presence of multiple diseases would be to explicitly include parameters that relate to all the possible joint disease states and obtain values for these parameters directly from the literature. It would then be entirely correct to sum costs and benefits over these states since they would be mutually exclusive. The difficulty is finding estimates of the baseline risks and treatment effects for the joint states in the literature.
Limitations
Our approach has a number of limitations. Fundamental to the latent variable formulation is the belief that the correlation structure in a multivariate normal continuous variable can, for our purposes, meaningfully model the correlation structure in the multivariate binary disease outcome. Multivariate normality implies that the correlation is independent of the mean marginal disease risks on the latent scale, but this is not true for the binary disease outcomes, where variances and covariances are functions of the mean.
If the latent variable Z i is considered to have a physical meaning, in that evidence suggests that each disease state arises when some underlying continuous process exceeds a threshold, our approach would seem reasonable on these grounds. However, if no such physical interpretation for the latent variable exists, the variable might be considered instead an artifact, included to introduce into the cost-effectiveness model information about the correlation structure in an external data set. In this case it may be necessary to consider carefully whether the marginal risks in the population from which the correlation structure is estimated are similar enough to those in the studies used to derive the risk estimates in the model, given the dependence between the correlation and mean in multivariate binary data.
In our case study the marginal risks of CHD, stroke, and diabetes were estimated as 172 per 1,000, 53 per 1,000, and 94 per 1,000 at baseline (no physical activity) and as 115 per 1,000, 38 per 1,000, and 67 per 1,000 in subjects who took exercise. Both baseline (no physical activity) and intervention (active) disease risks are somewhat higher in magnitude than the marginal disease risks estimated from the HSE data, which were 46 per 1,000 for CHD, 20 per 1,000 for stroke, and 33 per 1,000 for diabetes. Ideally we would estimate the baseline disease risk correlation using data from a sedentary population whose marginal disease risks are as close as possible to the baseline risk estimates we are using to parametrize the economic model. Likewise, intervention disease risk correlations would ideally be estimated using data from an active population with marginal disease risks similar to the intervention group risks used in the economic model. Last, we have been able to estimate the correlation between the disease states in our model from primary data. These data may not always be available, and in this case expert elicitation may be considered an option for learning about the correlations between disease states. The correlation parameters in our model essentially represent the correlations in underlying risks of disease, each expressed on a continuous scale, and their meaning, at least in a qualitative sense, could be expected to be fairly well understood intuitively. However, eliciting values for the correlation parameters is likely to be difficult, particularly for cases in which there are more than 2 disease states. 20 
CONCLUSIONS
This article presents an approach to synthesizing information relating to disease risk correlation with marginal risks and treatment effects to estimate joint risks and treatment effects in the absence of direct empirical data. The method allows us to determine the sensitivity of a model output to different assumptions about the correlation between disease risks and as such has the potential to strengthen the robustness of a prioritization decision.
APPENDIX A Chib and Greenberg's Method for Estimating the Correlation Matrix, Σ
We have binary data y ij relating to the presence or absence of j = 1; . . . ; J diseases on i = 1; . . . ; I individuals. We introduce a latent variable z ij that relates to y ij via y ij = Iðz ij > 0Þ, where Ið · Þ is the indicator function. We assume that z i = ðz i1 ; . . . ; z iJ Þ are realizations of the random variable Z i ∼ N J ðμ; ΣÞ.
The matrix, Σ, which must be in correlation form to ensure identifiability, 9 can be estimated from data using Bayesian methods. Under the multivariate probit model, proposed by Chib and Greenberg, 9 the likelihood for the data is where y = ðy 1 ; . . . ; y I Þ . This posterior not only is analytically intractable, given the form the likelihood takes, but also is very computationally intensive to sample from. Including Z i in the posterior as a nuisance parameter allows us to write where Z = ðZ 1 ; . . . ; Z I Þ . This posterior, although still analytically intractable, is now much easier to sample from. 9 The natural choice of distribution for prior knowledge concerning μ is the multivariate normal, and for Σ the inverse Wishart. 13 See appendix B for annotated BUGS code. 12, 27 APPENDIX B BUGS Code for Implementing Multivariate Probit Model model{ # i = 1,. . ., n indexes the number of individuals in the data set # j = 1,. . ., p indexes the number of diseases 
